Roche Holding AG

Over half of the compounds in Roche Company products pipeline are biopharmaceuticals, enabling them to deliver better-targeted therapies. They are specialized in Oncology, Neuroscience, Infectious Diseases, Immunology, Cardiovascular and Metabolism, Ophthalmology and Respiratory branches Medicines.

Facts About Company

Roche Holding annual revenues for year ending December 2022 was 63.28 billion CHF. (Previous year : 62.8 billion CHF)

Roche Holding annual operating profit for year ending December 2022 is 17.47 billion CHF. (Previous year : 18.15 billion CHF)

As on December 2022, Roche Holding has 103,613 employees, 29 research and development sites in Pharmaceuticals and Diagnostics worldwide, 23 manufacturing sites in Pharmaceuticals and Diagnostics worldwide.

63 million patients treated with medicines of Roche Holding.

Annual Results Summary

Roche Holding AG - Annual Results - Revenue and Net Profit - in Billion CHF

Annual Results	Revenue	Operating Income	Net Income
Dec-2023	60.44	15.39	11.49
Dec-2022	65.81	17.47	12.42
Dec-2021	62.80	18.15	13.93
Dec-2020	58.32	18.54	14.29
Dec-2019	61.46	17.55	13.49
Dec-2018	56.84	14.74	10.50
Dec-2017	53.29	13.00	8.63
Dec-2016	50.57		9.57
Dec-2015	48.10		8.80

Balance Sheet Summary

Roche Holding AG - Balance Sheet Summary - in Billion CHF

Yearly - Ending	Total Assets	Total Liabilities	Total Equity
Dec-2023	90.46	57.20	33.2
Dec-2022	88.15	63.97	32.0
Dec-2021	92.31	67.8	24.4
Dec-2020	87.88	50.0	37.8
Dec-2019	86.14	49.7	36.3